6 completed, 1 terminated, 1 unknown. 3 Phase 3, 3 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
| Phase 4 | 3 | Completed 3 |
| Not applicable | 1 | Terminated 1 |
Follow thienopyridine: new trials by email Literature Review of thienopyridine trials Research Report on thienopyridine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GORE® CARDIOFORM Septal Occluder Migraine Clinical Study Actual device PFO closure, Thienopyridine (clopidogrel or prasugrel), Sham device PFO closure - Migraine, Patent Foramen Ovale | Not applicable | Terminated | W.L.Gore & Associates | 7 | 2021-02-05 | 2026-06-09 |
| 3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation Aspirin, Thienopyridine - Coronary Artery Disease | Unknown | Teikyo University | 1500 | 2016-07-01 | 2016-08-02 | |
| Short and Optimal Duration of Dual Antiplatelet Therapy Study Thienopyridine for 3 months - Coronary Artery Disease | Phase 4 | Completed | Takeshi Morimoto | 1525 | 2012-09-01 | 2015-12-10 |
| Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty Bare Metal Stent, Drug-Eluting Stent, Blinded clopidogrel - Saphenous Vein Graft Atherosclerosis | Phase 4 | Completed | VA Office of Research and Development | 597 | 2012-01-11 | 2022-07-26 |
| Nobori Dual Antiplatelet Therapy as Appropriate Duration Aspirin or thienopyridine, Aspirin and thienopyridine - Coronary Artery Disease | Phase 4 | Completed | Associations for Establishment of Evidence in Interventions | 3773 | 2011-12-01 | 2017-01-27 |
| PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK) PROMUS Element Everolimus-Eluting Coronary Stent System, Aspirin, Thienopyridine - Coronary Artery Disease | Phase 3 | Completed | Boston Scientific Corporation | 22 | 2009-10-01 | 2019-03-26 |
| The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL) PROMUS Element Coronary Stent System, Aspirin, Thienopyridine - Coronary Artery Disease | Phase 3 | Completed | Boston Scientific Corporation | 102 | 2009-02-01 | 2019-03-26 |
| The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions PROMUS Coronary Stent System, PROMUS Element Coronary Stent System, Aspirin - Coronary Artery Disease | Phase 3 | Completed | Boston Scientific Corporation | 1530 | 2009-01-01 | 2019-03-27 |
Coronary Artery Disease (6) · Foramen Ovale, Patent (1) · Migraine Disorders (1) · Migraine with Aura (1)
Boston Scientific Corporation (3) · Associations for Establishment of Evidence in Interventions (1) · Takeshi Morimoto (1) · Teikyo University (1) · VA Office of Research and Development (1) · W.L.Gore & Associates (1)
Japan (6) · United States (5) · Australia (2) · Belgium (2) · France (2) · Latvia (2) · New Zealand (2) · Austria (1) · Denmark (1) · Finland (1) · Germany (1) · Malaysia (1) · Netherlands (1) · Poland (1) · Portugal (1)
Peter M. Maurer, MPH (2) · David Dodick, MD (1) · Emmanouil S Brilakis, MD PhD (1) · Ken Kozuma, MD, PhD (1) · Peter M Maurer, MPH (1) · Robert Sommer, MD (1) · Subhash Banerjee, MD (1) · Takeshi Kimura, MD, PhD (1)
PMID 29217001, PMID 21470815, PMID 24905795, PMID 28641838, PMID 29759512, PMID 32019343, PMID 34736721